These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36104378)

  • 1. Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure.
    Ejiri K; Miyoshi T; Kihara H; Hata Y; Nagano T; Takaishi A; Toda H; Namba S; Nakamura Y; Akagi S; Sakuragi S; Minagawa T; Kawai Y; Nishii N; Fuke S; Yoshikawa M; Nakamura K; Ito H;
    Sci Rep; 2022 Sep; 12(1):15449. PubMed ID: 36104378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus.
    Ejiri K; Miyoshi T; Kihara H; Hata Y; Nagano T; Takaishi A; Toda H; Nanba S; Nakamura Y; Akagi S; Sakuragi S; Minagawa T; Kawai Y; Nishii N; Fuke S; Yoshikawa M; Nakamura K; Ito H;
    J Am Heart Assoc; 2020 Aug; 9(16):e015103. PubMed ID: 32805185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
    Ejiri K; Miyoshi T; Nakamura K; Sakuragi S; Munemasa M; Namba S; Takaishi A; Ito H
    BMJ Open; 2019 Mar; 9(3):e026590. PubMed ID: 30928954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction.
    Nakashima M; Miyoshi T; Ejiri K; Kihara H; Hata Y; Nagano T; Takaishi A; Toda H; Nanba S; Nakamura Y; Akagi S; Sakuragi S; Minagawa T; Kawai Y; Nishii N; Fuke S; Yoshikawa M; Nakamura K; Ito H;
    ESC Heart Fail; 2022 Feb; 9(1):712-720. PubMed ID: 35267246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT).
    Koyama T; Tanaka A; Yoshida H; Oyama JI; Toyoda S; Sakuma M; Inoue T; Otsuka Y; Node K
    Heart Vessels; 2018 Aug; 33(8):958-964. PubMed ID: 29427024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
    Nakamura K; Oe H; Kihara H; Shimada K; Fukuda S; Watanabe K; Takagi T; Yunoki K; Miyoshi T; Hirata K; Yoshikawa J; Ito H
    Cardiovasc Diabetol; 2014 Jul; 13():110. PubMed ID: 25074318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
    Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
    Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
    Ayaori M; Iwakami N; Uto-Kondo H; Sato H; Sasaki M; Komatsu T; Iizuka M; Takiguchi S; Yakushiji E; Nakaya K; Yogo M; Ogura M; Takase B; Murakami T; Ikewaki K
    J Am Heart Assoc; 2013 Jan; 2(1):e003277. PubMed ID: 23525426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.
    Kawamori R; Tajima N; Iwamoto Y; Kashiwagi A; Shimamoto K; Kaku K;
    Lancet; 2009 May; 373(9675):1607-14. PubMed ID: 19395079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study.
    Kario K; Okada K; Murata M; Suzuki D; Yamagiwa K; Abe Y; Usui I; Tsuchiya N; Iwashita C; Harada N; Okawara Y; Ishibashi S; Hoshide S
    J Clin Hypertens (Greenwich); 2020 Sep; 22(9):1585-1593. PubMed ID: 32810338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
    Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.
    Fujitaka K; Otani H; Jo F; Jo H; Nomura E; Iwasaki M; Nishikawa M; Iwasaka T
    Endocr J; 2011; 58(6):425-32. PubMed ID: 21498915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Berg DD; Wiviott SD; Scirica BM; Gurmu Y; Mosenzon O; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Johanson P; Johansson PA; Langkilde AM; Raz I; Braunwald E; Sabatine MS
    Circulation; 2019 Nov; 140(19):1569-1577. PubMed ID: 31474116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luseogliflozin for the treatment of type 2 diabetes.
    Seino Y
    Expert Opin Pharmacother; 2014 Dec; 15(18):2741-9. PubMed ID: 25359155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes.
    Bando S; Ichikawa R; Taguchi T; Fujimoto K; Motomiya T; Taguchi M; Takano K; Shichiri M; Miyatsuka T
    Endocr J; 2022 Jun; 69(6):681-687. PubMed ID: 35067495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
    Fujitani Y; Fujimoto S; Takahashi K; Satoh H; Hirose T; Hiyoshi T; Ai M; Okada Y; Gosho M; Mita T; Watada H
    Diabetes Res Clin Pract; 2016 Nov; 121():146-156. PubMed ID: 27710821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
    Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
    Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
    Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
    Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.